Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Amneal Pharmaceuticals (NASDAQ:AMRX) reported its Q4 earnings results on Friday, March 1, 2024 at 06:00 AM.
Here's what investors need to know about the announcement.
Amneal Pharmaceuticals beat estimated earnings by 56.00000000000001%, reporting an EPS of $0.14 versus an estimate of $0.09.
Revenue was up $7.22 million from the same period last year.
Last quarter the company beat on EPS by $0.06 which was followed by a 6.0% drop in the share price the next day.
Here's a look at Amneal Pharmaceuticals's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
---|---|---|---|---|
EPS Estimate | 0.13 | 0.10 | 0.10 | 0.21 |
EPS Actual | 0.19 | 0.19 | 0.12 | 0.23 |
Revenue Estimate | 595.27M | 562.49M | 537.31M | 579.91M |
Revenue Actual | 620.04M | 599.05M | 557.54M | 609.76M |
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Amneal Pharmaceuticals management provided guidance for FY 2024, expecting earnings between $0.53 and $0.63 per share.
To track all earnings releases for Amneal Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: AMRX